Research programme: SB 9000 - Spring Bank Pharmaceuticals

Drug Profile

Research programme: SB 9000 - Spring Bank Pharmaceuticals

Alternative Names: MBI 1313; MX 1313; ORI 7246; SB 9000; SB 9001; SB 9002 1

Latest Information Update: 29 May 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MIGENIX
  • Developer Spring Bank Pharmaceuticals
  • Class Nucleotides; Small molecules
  • Mechanism of Action Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis B

Most Recent Events

  • 29 May 2013 Discontinued - Preclinical for Hepatitis B in USA (PO)
  • 19 Aug 2011 BioWest Therapeutics is now called Carrus Capital Corporation
  • 08 Apr 2010 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top